BioNTech Falls Short In Jittery IPO Market

Investors also readjust to firm's unproven pipeline

After ADC Therapeutics postponed its launch last week, BioNTech braves the markets but finds them less receptive than hoped.

Cautioin
Investors wary of jumping into public offerings • Source: Shutterstock

German biotech company BioNTech AG has raised $150m in its NASDAQ initial public offering, a much lower figure than it had hoped to generate.

This was around $100m less than its target, and reflects wider turbulence on the public markets. High profile IPOs from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Executives On The Move: New CEOs At Outlook Therapeutics And Peptomyc

Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.